Calliditas Therapeutics (CALT)
Free
No email, no account, no signup.
Pulling latest news for Calliditas Therapeutics…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
NEUTRAL
Sentiment
6/10
Risk
6/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Calliditas Therapeutics is a biopharma company focused on rare kidney diseases, with the commercial product **TARPEYO/Kinpeygo (delayed-release budesonide)** for IgA nephropathy. The company was acquired by **Asahi Kasei** in 2024 and delisted from Nasdaq Stockholm, meaning reporting and tradabil...
Exchange
NASDAQ
Type
Biotech
Sector
Biotech and orphan drugs (kidney diseases)
Market Cap
$2.2B
Market sentiment
Sentiment is **cautiously positive** around TARPEYO’s commercial potential, but discussion has faded post-delisting; attention is mainly on pipeline readouts and Asahi Kasei’s execution.
Why NEUTRAL ?
- The equity is **acquired/delisted**, making direct investment difficult or impossible for many investors.
- Exposure to the assets is effectively via **Asahi Kasei**.
- Key value drivers are **setanaxib data** and continued TARPEYO growth, but transparency may be lower post-acquisition.
- If you want exposure: consider Asahi Kasei (3407 JP) instead.
Recent News
- No material news has been identified after 2026-05-18. Calliditas remains delisted and wholly owned by Asahi Kasei, which limits standalone news flow and reporting transparency for Calliditas as a separate entity.
Bull case
- **Strong commercial momentum** for TARPEYO following full approvals (US/EU).
- **Pipeline updates** (setanaxib) could improve the upside case.
Unlock to read more →
Bear case
- **Delisting/information gap** may reduce transparency and liquidity.
Unlock to read more →
Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Calliditas Therapeutics – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.